Skip to content
Biodatica
Start free

Sichuan Baili Pharmaceutical Co., Ltd.

Beijing, Beijing Municipality

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

9mo agoTrial registeredSep 26, 2025Source filing (opens the source filing in a new tab)

Momentum

54no change

Momentum 54 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,798 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Oct 17, 2024

    Recurrent Glioblastoma · RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

    ClinicalTrials.gov · NCT06598787 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Feb 10, 2023

    Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

    ClinicalTrials.gov · NCT05485753 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources